Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Phase 1 data announced for VRDN-008, a half-life extended bispecific FcRn inhibitor.
Viridian Therapeutics, Inc.\DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Phase 1 data announced for VRDN-008, a half-life extended bispecific FcRn inhibitor
- Results come from healthy volunteers, providing early safety, pharmacokinetic and dosing evidence
- Exhibit 99.1 contains the detailed trial findings, critical for assessing clinical differentiation and development potential
Item 8.01 · Other Events
- VRDN-008 achieved 74% peak IgG reduction in six healthy volunteers, supporting potential FcRn inhibitor efficacy
- Half-life 15 to 18 days, enabling targeted Q8W subcutaneous dosing
- Safety profile generally well tolerated, with albumin and low-density lipoprotein sparing
- Planned pivotal MG trial in mid-2027, testing Q4W and Q8W dosing versus placebo
- Development focus shifts to VRDN-008, with VRDN-006 potentially deferred
Item EX-99.1 · Exhibit EX-99.1
- Phase 1 supports VRDN-008’s potential differentiation: 74% peak IgG reduction sustained through 8 weeks
- Half-life 15–18 days, up to 6x longer than first-generation Fc fragments
- Safety profile generally well tolerated, with albumin and LDL spared and no serious adverse events
- Registrational MG trial planned for mid-2027, testing Q4W and Q8W dosing versus placebo
- At-home enFuse delivery could strengthen convenience and commercial positioning across autoimmune diseases
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Viridian Therapeutics, Inc.\DE 8-K filings
Get the next VRDN 8-K as it lands
Follow VRDN for push alerts, or ask the research agent what this filing means.